Private Advisor Group
IBRX icon

Private Advisor Group’s ImmunityBio IBRX Stock Holding History

Private Advisor Group’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$8.35M Buy
884,599
+718,645
+433% +$5.74M 0.03% 558
2026
Q2 		$1.45M Sell
165,954
-1,482,602
-90% -$11.2M 0.01% 1171
2026
Q1 		$12.6M Buy
1,648,556
+1,487,482
+923% +$10.2M 0.06% 340
2025
Q4 		$319K Buy
161,074
+148,222
+1,153% +$336K ﹤0.01% 2116
2025
Q3 		$31.6K Sell
12,852
-203
-2% -$523 ﹤0.01% 2479
2025
Q2 		$34.5K Buy
13,055
+203
+2% +$546 ﹤0.01% 2370
2025
Q1 		$38.7K Sell
12,852
-598
-4% -$1.81K ﹤0.01% 2247
2024
Q4 		$34.4K Sell
13,450
-41,317
-75% -$172K ﹤0.01% 2227
2024
Q3 		$204K Sell
54,767
-32,140
-37% -$149K ﹤0.01% 2205
2024
Q2 		$549K Buy
86,907
+76,407
+728% +$504K ﹤0.01% 1512
2024
Q1 		$56.4K Hold
10,500
– – ﹤0.01% 2238
2023
Q4 		$52.7K Buy
+10,500
New +$32.9K ﹤0.01% 2159
2020
Q3 		– Sell
-500
Closed -$6K – 2450
2020
Q2 		$6K Buy
+500
New +$2.82K ﹤0.01% 3163

Other funds holding IBRX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
SEB Asset Management
SEB Asset Management Stockholm $27B AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Clearwater Capital Advisors
Clearwater Capital Advisors Hoffman Estates, Illinois $1.39B AUM 12.56% 1-Year Est. Return
AH
Allen Holding New York $1.15B AUM 24.01% 1-Year Est. Return

Private Advisor Group's IBRX Position: Q3 2026 in Review

Private Advisor Group increased its ImmunityBio (IBRX) stake by 433% in Q3 2026, buying an estimated $5.74M and bringing the position to 884,599 shares worth $8.35M. The position accounts for 0.03% of the portfolio, ranked #558.

Private Advisor Group first reported a position in IBRX in Q2 2020 and has held it in 13 quarters since. The position peaked at $12.6M in Q1 2026. 231 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

  • Private Advisor Group held 884,599 shares of ImmunityBio worth $8.35M as of Q3 2026.
  • Private Advisor Group bought 718,645 ImmunityBio shares in Q3 2026, an estimated $5.74M.
  • ImmunityBio made up 0.03% of Private Advisor Group's portfolio in Q3 2026, its #558 holding.
  • Private Advisor Group first reported a position in ImmunityBio in Q2 2020 and has held it in 13 quarters since.
  • Private Advisor Group's ImmunityBio position peaked at $12.6M in Q1 2026.
  • 231 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on Private Advisor Group's 13F filing for Q3 2026, filed 10 Nov 2026.